Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
1.07
USD
-4.46%
+15.05%
-20.74%
This article is reserved for members
Not a member ?
Free registration
Top Premarket Decliners
Apr. 18
MT
Sector Update: Health Care Stocks Retreating Late Afternoon
Apr. 17
MT
Top Midday Gainers
Apr. 17
MT
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly
Apr. 17
MT
Top Premarket Gainers
Apr. 17
MT
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 16
CI
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC
Apr. 07
CI
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC
Apr. 04
CI
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
Feb. 08
CI
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
Feb. 08
CI
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
Feb. 08
CI
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.
Dec. 28
CI
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal
Dec. 11
CI
Top Premarket Gainers
Nov. 14
MT
Earnings Flash (INVO) INVO BIOSCIENCE Reports Q3 Revenue $974,894
Nov. 13
MT
INVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 13
CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks
Nov. 10
MT
Transcript : INVO Bioscience, Inc., NAYA Biosciences Inc. - Special Call
23-10-31
Sector Update: Health Care Stocks Softer Late Afternoon
23-10-23
MT
Sector Update: Health Care Stocks Mixed in Monday Afternoon Trading
23-10-23
MT
INVO Bioscience Shares Skyrocket After Signing Deal to Buy NAYA Biosciences
23-10-23
MT
Wall Street Set to Open Lower Monday as National Activity Index Shows Near-Historic Economic Growth
23-10-23
MT
NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. in a reverse merger transaction for $90.7 million.
23-10-22
CI
Transcript : INVO Bioscience, Inc., Q2 2023 Earnings Call, Aug 14, 2023
23-08-14
Earnings Flash (INVO) INVO BIOSCIENCE Posts Q2 Revenue $315,902, vs. Street Est of $450,000
23-08-14
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Companyâs flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the womanâs body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.
More about the company
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**